Jubilant Pharmova Jumped 3.55% to ₹965.00 After Block Deal Update — Levels, Volumes and the Follow-Up to Track

Jubilant Pharmova: what is happening in Monday's session

Jubilant Pharmova (JUBLPHARMA) last traded at ₹965.00, +33.10 (+3.55%) against a previous close of ₹931.90, read from the NSE board at the close of the last trading session on Monday, 12 October 2026. On the tape the move is large enough to stand out from the index, so it is being driven by something specific to the company rather than by market beta.

The market is closed at the time of writing (Tuesday, 02:05 am IST); the levels below are the close of the Monday, 12 October 2026 session.

Highlights

• Where it trades: Jubilant Pharmova is at ₹965.00, +33.10 (+3.55%) versus the previous close of ₹931.90.
• Why it is moving: a block-deal story — one business desk filed on the company in the last few hours.
• Today's band: ₹908.00 to ₹969.90, against an open of ₹931.90 — the stock is defending its opening print.
• Twelve-month context: 18.55% below the ₹1,185 high and 22.77% above the ₹786 low, so the stock sits in the middle part of its own range.
• Participation: turnover is running at 5.7x the twenty-day average, so institutions are transacting rather than retail nibbling.
• What to watch: who the counterparties were and whether the buyer is a long-only fund or a trading desk, because a lock-in changes how much of the supply actually returns to the market.

The block deal angle

The reason Jubilant Pharmova is on the desks in Monday's session is a block deal story — reported by one desk so far, with the headlines linked below. Large negotiated trades change the shareholder register in one print, and the discount or premium at which the block clears is the cleanest read on what institutions think the stock is worth today.

The board at a glance

How the session has traded

Jubilant Pharmova has traded between ₹908.00 and ₹969.90 in this session against an open of ₹931.90 and a previous close of ₹931.90. That is a band of ₹61.90, or 6.41% of the current price — a wide day, which means intraday positions are being forced rather than chosen.

Holding above the open at ₹931.90 matters because it is the level intraday desks use as the session pivot: buyers who entered at the open are in profit, so there is no forced supply from that cohort.

In market-structure terms this is a repricing session rather than a drift session, and repricing sessions are confirmed or rejected by the next day's low, not by the close.

What a block deal tells you that the screen price does not

A block or bulk deal is a negotiated trade executed in one print, usually between an institution reducing a position and one or several buyers taking it on. Because both sides agree a price before the trade hits the tape, the discount or premium to the prevailing market price is the single cleanest read available on what large money thinks Jubilant Pharmova is worth today.

The identity of the buyer matters more than the size. A long-only fund taking delivery implies the paper is off the market for quarters; an arbitrage or trading desk taking it implies the same stock returns as supply within weeks. Exchange bulk-deal disclosures name both sides after the close, which is why the day-after reaction is often more informative than the day-of one.

On the board, JUBLPHARMA is at ₹965.00 against a session range of ₹908.00 to ₹969.90. If the block cleared inside that range, the market has already absorbed it; a block struck well below the range low usually caps the stock until the buyer stops adding.

The longer-horizon picture

What the returns table is saying

Over the last week Jubilant Pharmova has slipped -3.43% and over the month -3.28%. Both horizons pointing the same way means the recent move is an extension of the existing trend rather than a reversal.

The twelve-month return of -12.07% is the context long-term holders judge the stock on. A moderate one-year move means the stock has broadly tracked its earnings path rather than being re-rated in either direction.

Reading the price against its own ranges

Over the last twelve months the price has covered ₹786 to ₹1,185. The current level is 45% of the way through that band, 18.55% below the 52-week high and 22.77% above the 52-week low. A mid-range price means neither the bulls nor the bears own the trend yet; the twelve-month extremes are the levels that decide which way the range resolves.

Traded quantity of 14,19,970 shares is 5.69x the 20-day average of 2,49,392. Volume expansion of this order alongside a price move is the classic confirmation signal — institutions cannot build or exit positions quietly, so unusual turnover normally means larger hands are active.

What the newswires are reporting

Headlines are listed for context and link straight to the publisher. The prices, ranges and tables on this page are read independently from exchange data at the timestamp shown.

• Jubilant Pharmova block deal: Quant Mutual Fund offloads Rs 190 crore stake amid Rs 800 crore fundraising plan; Abakkus buys 11 lakh shares — Economic Times

What decides the next session

For this block deal story specifically, watch who the counterparties were and whether the buyer is a long-only fund or a trading desk, because a lock-in changes how much of the supply actually returns to the market. On the chart, the ₹969.90 high and ₹908.00 low of the last session are the reference levels — a higher low in the next session turns a headline reaction into a trend, a break of that low usually voids it. Participation is the third check: the move needs turnover at or above the stock's own 20-day average of 2,49,392 shares to be read as positioning rather than a squeeze.

How to read this as an investor

For a trader, the immediate question is not direction but whether the repricing holds. ₹969.90 and ₹908.00 are the day's markers; the next session's ability to keep the move inside that band — a higher low after an up-move, a lower high after a fall — is what separates a trend from a one-day event.

For a long-term shareholder, supply-driven weakness is a different thing from deterioration. Nothing in this event changes what the company earns; it changes who owns it and at what price. The question worth asking is whether the post-event share count and the use of proceeds leave earnings per share better or worse than before.

On risk: this report is a reading of live exchange data at a point in time, and intraday levels change. Position sizing — not conviction about the story — is what determines the outcome of a trade built on a headline, and averaging into a falling price without a change in the underlying facts is how a trade becomes an unintended long-term holding.

In summary

Jubilant Pharmova is being bought on a block-deal story, and at ₹965.00 the move is backed by turnover well above its own average, which is the version of a rally that tends to hold. The day's ₹908.00–₹969.90 band is the frame for the next session, and who the counterparties were and whether the buyer is a long-only fund or a trading desk is what resolves the story either way.

Where to track JUBLPHARMA next

Live price, charts and technicals stay on the Jubilant Pharmova stock page, and every filed quarter is tabulated on its quarterly results page. Both pages refresh from the exchange feed through the session, so they carry a later reading than this report once the market has moved on.

Frequently asked questions

What is the Jubilant Pharmova share price in Monday's session?

Jubilant Pharmova (JUBLPHARMA) last traded at ₹965.00, +33.10 (+3.55%) against the previous close of ₹931.90, read from the NSE board at the close of the last trading session on Monday, 12 October 2026.

Why is Jubilant Pharmova in the news in Monday's session?

1 business publisher ran headlines on the company in the last session — a block deal story. Their reports are linked above; the levels and tables here are read independently from exchange data.

What is the 52-week high and low of JUBLPHARMA?

Over the last twelve months JUBLPHARMA has traded between a low of ₹786 and a high of ₹1,185, computed from the adjusted daily series.

Is JUBLPHARMA up or down in Monday's session?

JUBLPHARMA gained +3.55% in the last session, trading between ₹908.00 and ₹969.90 against an open of ₹931.90.

Is the market open right now?

No. The market is closed at the time of writing (Tuesday, 02:05 am IST); the levels below are the close of the Monday, 12 October 2026 session.

Key takeaways

• Last price: ₹965.00 (+3.55%) — higher at the time of writing
• Day range: ₹908.00 – ₹969.90
• 52-week high: ₹1,185

About this report

Every figure on this page is read from a primary source at the timestamp shown — exchange boards for equities and indices, the exchange bid book for IPOs, published association rates for bullion, and consolidated exchange quotes for crypto — with no estimation or third-party commentary. Historical fields such as trailing returns and 52-week extremes are computed on the adjusted daily series so splits and bonuses do not create false gaps. A timestamp outside market hours reflects the last traded or last published value, not a live tick.

Related live pages

• Jubilant Pharmova share price
• Jubilant Pharmova quarterly results
• Stocks in news
• Top gainers
• Market dashboard

Sources

• NSE live board data via our exchange data feed
• Headline attribution links above point to the original publishers
• TrendRipperX Jubilant Pharmova stock page

“This report is generated automatically from live exchange and official association data at the time stamped above. Prices move continuously — verify on the source before acting. Nothing here is investment advice.”